Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• KRAS mutations are key drivers in non-small cell lung cancer (NSCLC), particularly lung adenocarcinomas.
• Targeting KRAS directly is challenging, leading to indirect approaches with limited clinical success.
• Understanding the role of wild-type (WT) KRAS is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate the influence of WT KRAS on signaling networks and druggable targets in KRAS-mutant lung adenocarcinomas.
• To identify potential vulnerabilities arising from the loss of WT KRAS.
• To explore new therapeutic avenues for NSCLC patients with KRAS mutations.

Main Methods:

• Utilized commercially available KRAS-mutant lung adenocarcinoma cell lines.
• Employed reverse-phase protein microarray (RPPA) to analyze expression/activation of 183 signaling proteins.
• Validated key findings in 23 surgical biospecimens using RPPA.

Main Results:

• Detected kinase-driven signatures along MAPK and AKT/mTOR signaling pathways associated with WT KRAS allele presence.
• Observed alterations in cell cycle regulators in tumors with WT KRAS.
• Identified FoxM1 as a potential vulnerability in both cell lines and clinical samples retaining WT KRAS.

Conclusions:

• Loss of WT KRAS influences signaling events and druggable targets in KRAS-mutant lung adenocarcinomas.
• FoxM1 represents a promising therapeutic target for tumors with WT KRAS.
• Findings suggest novel strategies for treating KRAS-mutant lung cancer by targeting WT KRAS-associated vulnerabilities.